NO20043832L - Oral fast losningsformulering av en darlig vannloselig aktiv substans - Google Patents

Oral fast losningsformulering av en darlig vannloselig aktiv substans

Info

Publication number
NO20043832L
NO20043832L NO20043832A NO20043832A NO20043832L NO 20043832 L NO20043832 L NO 20043832L NO 20043832 A NO20043832 A NO 20043832A NO 20043832 A NO20043832 A NO 20043832A NO 20043832 L NO20043832 L NO 20043832L
Authority
NO
Norway
Prior art keywords
active substance
solid solution
poorly water
oral solid
soluble active
Prior art date
Application number
NO20043832A
Other languages
English (en)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20043832L publication Critical patent/NO20043832L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043832A 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans NO20043832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
NO20043832L true NO20043832L (no) 2004-09-13

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043832A NO20043832L (no) 2002-02-14 2004-09-13 Oral fast losningsformulering av en darlig vannloselig aktiv substans

Country Status (24)

Country Link
US (2) US20050008697A1 (no)
EP (1) EP1476196B1 (no)
JP (1) JP2005517041A (no)
KR (1) KR101014545B1 (no)
CN (1) CN1273194C (no)
AR (1) AR038681A1 (no)
AT (1) ATE345817T1 (no)
AU (1) AU2003208713B2 (no)
BR (1) BR0307278A (no)
CA (1) CA2472744A1 (no)
DE (1) DE60309839T2 (no)
DK (1) DK1476196T3 (no)
ES (1) ES2277635T3 (no)
HR (1) HRP20040613A2 (no)
IL (2) IL162883A0 (no)
MX (1) MXPA04007852A (no)
NO (1) NO20043832L (no)
PL (1) PL370452A1 (no)
PT (1) PT1476196E (no)
RU (1) RU2314811C2 (no)
SI (1) SI1476196T1 (no)
UA (1) UA79267C2 (no)
WO (1) WO2003068266A1 (no)
ZA (1) ZA200405608B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
AU2007259252A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Oral pharmaceutical composition of a poorly water-soluble active substance
EP2037890A1 (en) * 2006-06-22 2009-03-25 Solvay Pharmaceuticals B.V. Oral pharmaceutical composition of a poorly water-soluble active substance
ES2363452T3 (es) * 2006-07-06 2011-08-04 Ares Trading S.A. Una composición farmacéutica oral de una anilinopirimidina, su preparación y uso de la misma.
EP1945184A2 (en) * 2006-09-01 2008-07-23 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AR082560A1 (es) * 2010-08-04 2012-12-19 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6’-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina
SI2600851T1 (en) 2010-08-04 2018-07-31 Gruenenthal Gmbh PHARMACEUTICAL FORM OF DOSAGE COVERING 6'-FLUORO- (N-METHYLLINE N, N-DIMETHYL-4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO- (CYCLOHEXANE-1,1'- PIRANO (3,4, B) INDOL) -4-AMIN, FOR NON-PROPHETIC DISEASE TREATMENT
WO2017004733A1 (zh) * 2015-07-03 2017-01-12 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CA3120999C (en) * 2018-11-30 2025-04-01 Chemocentryx, Inc. Capsule formulations
CN121532170A (zh) * 2023-07-18 2026-02-13 三亚制药株式会社 含普仑司特的药物组合物的制备方法以及通过所述制备方法制备的药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
AU737053B2 (en) * 1997-01-30 2001-08-09 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
PL370452A1 (en) 2005-05-30
IL162883A (en) 2009-05-04
DE60309839T2 (de) 2007-03-15
RU2314811C2 (ru) 2008-01-20
US20110086844A1 (en) 2011-04-14
JP2005517041A (ja) 2005-06-09
SI1476196T1 (sl) 2007-04-30
AU2003208713B9 (en) 2003-09-04
UA79267C2 (en) 2007-06-11
AU2003208713A1 (en) 2003-09-04
AU2003208713B2 (en) 2007-10-18
AR038681A1 (es) 2005-01-26
CN1633307A (zh) 2005-06-29
HRP20040613A2 (en) 2005-04-30
ATE345817T1 (de) 2006-12-15
EP1476196B1 (en) 2006-11-22
KR20040085193A (ko) 2004-10-07
MXPA04007852A (es) 2004-10-15
RU2004127457A (ru) 2005-04-20
WO2003068266A1 (en) 2003-08-21
ZA200405608B (en) 2005-06-24
ES2277635T3 (es) 2007-07-16
US20050008697A1 (en) 2005-01-13
IL162883A0 (en) 2005-11-20
PT1476196E (pt) 2007-02-28
CN1273194C (zh) 2006-09-06
HK1077218A1 (en) 2006-02-10
DK1476196T3 (da) 2007-03-05
CA2472744A1 (en) 2003-08-21
DE60309839D1 (de) 2007-01-04
KR101014545B1 (ko) 2011-02-16
BR0307278A (pt) 2004-12-28
EP1476196A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
FIU20070036U0 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
PL376483A1 (pl) Sposób wytwarzania doustnej postaci leku o natychmiastowym rozpadzie i uwalnianiu substancji czynnych
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
DK2258394T3 (da) Oral doseringsform omfattende en PDE 4-inhibitor som en aktiv bestanddel og polyvinylpyrrolidon som excipiens
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
PT1501534E (pt) Formulacoes farmaceuticas
CY2018005I1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20033384D0 (no) Farmasöytisk formulering
ATE388703T1 (de) Pharmazeutische formulierung des telmisartan natriumsalzes
NO20026209L (no) Endoparasitticidale midler for frivillig oralt inntak av dyr
DE60210784D1 (de) Orale antidiabetische wirkstoffe
AU2003208761A1 (en) A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
FR2904219B1 (fr) Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
AU2003302888A1 (en) Oral formulations for poorly absorptive hydrophilic drugs
AU2003244259A1 (en) Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient
EP1581196A4 (en) SÄURELABILE MEDICINAL COMPOSITIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application